Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Relatlimab - Bristol-Myers Squibb/Ono Pharmaceuticals

Next Previous
X
Search
Drug Profile

Relatlimab - Bristol-Myers Squibb/Ono Pharmaceuticals

Alternative Names: Anti-LAG-3; Anti-LAG-3 monoclonal antibody - Bristol-Myers Squibb; Anti-LAG-3-Bristol-Myers-Squibb; Anti-lymphocyte activation gene 3 monoclonal antibody; BMS 986016; ONO-4482

Latest Information Update: 08 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Herlev Hospital; Multiple Myeloma Research Consortium; National Institute of Neurological Disorders and Stroke; Ono Pharmaceutical; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; UCLAs Jonsson Comprehensive Cancer Center; University Hospital of Essen; University of Miami; University of Pittsburgh
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD223 antigen inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Chordoma; Colorectal cancer; Gastric cancer; Head and neck cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Soft tissue sarcoma; Solid tumours; Uveal melanoma
  • Phase I/II Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Fallopian tube cancer; Hodgkin's disease; Mantle-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Oesophageal cancer; Ovarian cancer; Peritoneal cancer
  • No development reported Glioblastoma

Most Recent Events

  • 24 Jul 2024 Bristol-Myers Squibb terminated a phase-I trial in Malignant melanoma (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA, Canada, Germany, Spain, Belgium (IV) due to change in business objectives (NCT03978611) (EudraCT2019-000132-25)
  • 28 Jun 2024 No recent reports of development identified for phase-I development in Glioblastoma(Combination therapy, Recurrent, Second-line therapy or greater) in USA (IV, Infusion)
  • 28 Jun 2024 No recent reports of development identified for phase-I development in Glioblastoma(Monotherapy, Recurrent, Second-line therapy or greater) in USA (IV, Infusion)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top